Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
RESEARCH TOOLSreports
Acurx Pharmaceuticals (ACXP) Stock Price & Analysis
104 Followers
ACXP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.17 - $8.82
Previous Close$2.01
Volume51.99K
Average Volume (3M)106.71K
Market Cap
$29.08M
Enterprise Value$21.58M
Total Cash (Recent Filing)$7.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.7
Beta0.03
Next Earnings
May 09, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding15,757,102
10 Day Avg. Volume111,989
30 Day Avg. Volume106,706
Standard Deviation0.48
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)6.79
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$12.00Price Target Upside506.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Acurx Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessIbezapolstat demonstrated a pooled clinical cure rate of 96% across two Phase 2 studies in CDI patients.
Regulatory AdvancementPhase 3 trial designs are in accordance with the FDA's recent draft guidance, suggesting a streamlined regulatory path.
Strategic PartnershipsManagement is considering strategic partnerships that could provide additional capital and facilitate market entry in the EU or Japan.
Bears Say
Clinical And Regulatory RisksRisks include potential failure or equivocal data in Phase 3 trials and failure to secure regulatory approval.
Clinical Trial ProgressThe company has moderated its price target due to an updated timeline for the Phase 3 trials start.
Regulatory And Commercial RisksRisks include potential failure in the Phase 3 trial, challenges in securing regulatory approval, and the possibility of a smaller than anticipated commercial opportunity.
---
Ownership Overview
15.07% Insiders
3.65% Mutual Funds
5.39% Other Institutional Investors
75.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $1.17 and its highest was $8.82 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Currently, no data Available
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is May 09, 2024 which is in 16 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Mar 18, 2024. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$0.125.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -$0.15.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 14,468,229 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went down -4.779%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
---
Acurx Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (506.06% Upside)
$12.00 (506.06% Upside)
Blogger Sentiment
Bullish
ACXP Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $70.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.86%
12-Months-Change
Fundamentals
Return on Equity
-243.33%
Trailing 12-Months
Asset Growth
-17.78%
Trailing 12-Months
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
---
ACXP Earnings Call
Q4 2024
0:00 / 0:00
---
ACXP Stock 12 Months Forecast
Average Price Target
$12.00
▲(506.06% Upside)
Technical Analysis
Best Analysts Covering ACXP
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-15.12%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -15.12% per trade.
---